| YZY Biopharma | 武汉友芝友生物制药有限公司（YZY Biopharma）一家专门从事以肿瘤免疫疗法为核心的生物制药公司，专注于双特异性抗体药物的研发与产业化。 现有研发管线涵盖肿瘤、炎症和心血管等重大疾病领域。其中治疗胃癌、乳腺癌（HER2/CD3）和治疗晚期癌性腹水（EpCAM/CD3）的2个产品已率先在中国获批，成为该领域首个和第二个获批并开展临床研究的公司。 | YZY Biopharma is a biopharmaceutical company specialising in oncology immunotherapy, focusing on the development and industrialisation of bispecific antibody drugs. The existing R&D pipeline covers major diseases such as oncology, inflammation and cardiovascular diseases. Two of its products for the treatment of gastric cancer and breast cancer (HER2/CD3) and advanced cancer ascites (EpCAM/CD3) have received their clinical approvals in China and are in clinical stage. |
| Boan Biotech | 博安生物为绿叶制药集团的控股子公司，专业从事治疗用抗体开发，专注于包括肿瘤、代谢、自身免疫及眼科等常见主要治疗领域。公司的抗体发现活动围绕三大平台展开，即全人抗体转基因小鼠及噬菌体展示技术平台、双特异 T-cell Engager 技术平台、抗体药物偶联（ADC）技术平台。目前，博安生物已拥有1款商业化产品以及12种在研药物，Denosumab biosimilar 是一种治疗骨质疏松的重组抗RANKL全人单克隆抗体注射液，已完成预先注册（NDA备案） | Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on key therapeutic areas including oncology, metabolism, autoimmunity and ophthalmology. Boan Biotech’s antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed a commercialized product and a total of 12 drug candidates. Denosumab biosimilar is a recombinant anti-RANKL fully human monoclonal antibody injection for Osteoporosis，completed pre-registration. |
| Increasepharm Corp. | 北京盈科瑞创新医药股份有限公司是中药研发细分领域龙头企业。盈科瑞是以自主研发为主，CRO研发服务为辅，制剂领域新药研发独具特色，全研发链条的高新技术企业。YKRH00111是对I型糖尿病和II型糖尿病均有效果的小分子药物，处于临床前研究阶段。 | Beijing Increasepharm Corporation Limited is a segmentation leading enterprises of TCM with the R&D whole process. The company has five major business sections, including TCM, chemical medicine innovation, clinical service, pilot-scale production and international business. YKRH00111 is a small molecule that has effect on Type 1 diabetes and Type 2 diabetes and is in preclinical stages. |
| VivaVision Biotech | VivaVBision是一家专注于眼科的临床阶段生物技术公司。其两个主要产品处于临床二期试验。VVN001治疗干眼症（DED）最近在美国完成了临床二期试验，取得了很好的效果，目前正在中国进行临床二期试验；VVN539治疗青光眼也即将在美国临床进行试验。此外，VVN461已在中国进入第一阶段，旨在治疗葡萄膜炎（非类固醇药物）和潜在的多种适应症。 | VivaVBision is a clinical stage Biotech company focusing in ophthalmology. We have two assets in phase 2 clinical trials: VVN001 for dry eye disease (DED) recently completed Phase 2 in the US with excellent results and currently in the midst of phase 2 trial in China, and VVN539 for glaucoma (POAG) just about to enroll the first patient in the US phase 2 trial. In addition, we have VVN461 entering phase 1 in China, and is aiming for uveitis (non-steroid drug) and potentially for multipl indications. |
| Innogen Pharma | 银诺源医药是一家高科技、创新驱动的国际医药研发和制造公司。致力于糖尿病和代谢性疾病创新生物药的研发和产业化，目前在糖尿病和代谢性疾病领域拥有多个创新药物产品。其主要产品YN-011，是人源长效的GLP-1药物，用于治疗2型糖尿病（T2DM），非酒精性脂肪性肝炎以及肥胖， 2022年进入三期临床试验。 | Innogen Pharmaceutical is a high-tech, innovation-driven international pharmaceutical R&D and manufacturing company. Innogen Pharma is dedicated to the development and industrialization of innovative biologics for diabetes and metabolic diseases, and now has a number of innovative drug products in the field of diabetes and metabolic diseases. Its leading asset, YN-011, is long-acting GLP-1 for the treatment of T2D，NASH and Obesity, entering Phase III clinical trials in 2022. |
| TianTai Yinkang Biopharma | 银康生物是一家全球性的生物技术公司，主要针对罕见疾病，包括肿瘤学和免疫肿瘤学癌症治疗。其主要的候选药物，抗PD-1的 Yinkang001和抗CD20的Yinkang002处于临床1期，其他药物处于临床前研究阶段。 | Yinkang Biopharma is a global biotechnology company. Our approach is aimed primarily on rare disease, including oncology and immuno-oncology biotherapeutics. Its leading assests Yingkang 001（Anti-PD-1） and Yingkang 002(Anti-CD20) are in phase 1, and others are in precreclinical stage. |
| Bilayer Therapeutics | Bilayer Therapeutics公司是一家生物技术公司，致力于开发治疗便秘和其他结肠疾病的第一类疗法。其主要候选药物为BL-010，是一种以胆汁酸为基础的治疗便秘的FIC药物。通过专有的双层片剂技术提供天然胆汁酸，该公司正在开发针对慢性特发性便秘、伴有便秘的肠易激综合征和其他结肠疾病的创新疗法。 | Bilayer Therapeutics™, Inc. was formed to develop BL-010, a bile acid-based, first-in-class therapeutic for constipation and to deliver drugs for other diseases of the colon via a proprietary bilayer tablet technology. With a naturally occurring bile acid delivered via proprietary bilayer tablet technology, the company is developing innovative treatments for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation and other conditions of the colon. |
| J2H Biotech | J2HBiotech 是新药开发商，其目标是通过与世界各地的合作伙伴持续合作, 提高新药开发的成功率。J2H有非酒精性脂肪肝和肿瘤的产品管线，J2H拥有PROTAC(蛋白降解靶向嵌合体)技术，可以开发抗癌药物。J2H-1702是一种11β-HSD1抑制剂，用于治疗非酒精性脂肪肝炎，目前该项目已完成临床一期。 | J2H Biotech is a new drug development company. J2H aim to increase the success rate of new drug development by focusing capabilities and resources through continuous cooperation with partners world wide. J2H has Nash, oncology pipeline which is under development and has PROTAC (Proteolysis targeting chimera) technology that can be developed as an anti cancer drug. J2H-1702 is an 11β-HSD1 inhibitor for the treatment of non-alcoholic steatohepatitis, which has completed its clinical phase 1. |
| Ocuphire Pharma | Ocuphire Pharma是一家处于临床阶段的眼科生物制药公司，专注于开发治疗屈光和视网膜疾病，该公司的市值为4028万美元。其产品管线包括Nyxol滴眼液和APX3330。Nyxol用于治疗夜视障碍、逆转药物诱发的眼球震荡和老花眼，已经完成临床三期试验。 | Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The company has a market capitalisation of $40.28 million. Its products include Nyxol Eye Drops and APX3330. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia and has completed Phase 3 trials. |
BioToChina.org 